Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY (ganaxolone) Oral Suspension CV
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY® (ganaxolone) oral suspension CV. The new …
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY (ganaxolone) Oral Suspension CV Read More